Table 1. Baseline characteristics of the included studies.

SD: standard deviation; HBA1C: glycated hemoglobin; BMI: body mass index; No.: number of patients; N/A: not applicable

Study

Study design

Total no. of patients

No. of patients

Age (Mean±SD)

Male sex No. (%)

BMI kg/m2 (Mean±SD)

HBA1C % (Mean±SD)

Systolic blood pressure (Mean ±SD)

Diastolic blood pressure (Mean ±SD)

White No. (%)

Black No. (%)

Asians No. (%)

others No. (%)

Finerenone

Placebo

Finerenone

Placebo

Finerenone

Placebo

Finerenone

Placebo

Finerenone

Placebo

Finerenone

Placebo

Finerenone

Placebo

Finerenone

Placebo

Finerenone

Placebo

Finerenone

Placebo

Finerenone

Placebo

Bakris (2020) [13]

RCT

5674

2833

2841

65.4± 8.9

65.7±9.2

1953 (68.9)

2030 (71.5)

31.1 ± 6.0

31.1 ± 6.0

7.7± 1.3

7.7± 1.4

138.1±14.3

138.0± 14.4

75.8 ± 9.7

75.8 ± 9.7

1777 (62.7)

1815 (63.9)

140 (4.9)

124 (4.4)

717 (25.3)

723 (25.4)

199 (7.0)

179 (6.3)

Bertram (2021) [10]

RCT

7352

3686

3666

64.1± 9.7

64.1±10

2528 (68.6)

2577 (70.3)

31.5 ± 6.0

31.4 ± 5.9

7.7± 1.4

7.7± 1.4

135.8±14.0

135.7± 14.1

76.8 ± 9.5

76.8 ± 9.6

2672 (72.5)

2605 (71.1)

113 (3.1)

145 (4.0)

715 (19.4)

739 (20.2)

177 (4.8)

170 (4.6)

Gerasimos (2021) [14]

RCT

5674

2833

2841

65.5± 8.8

65.8±9

1953 (68.9)

2030 (71.4)

31.1±6

31.1±6

7.7± 1.3

7.7± 1.4

138± 14.3

138± 14.4

75.8± 9.7

75.8± 9.6

1717(60.6)

1815 (63.8)

140 (4.9)

124 (4.3)

717 (25.3)

723 (25.4)

N/A

N/A

Agarwal (2022) [5]

RCT

13026

6519

6507

64.7 ±  9.4

64.8 ± 9.7

4481 (68.7)

4607 (70.8)

N/A

N/A

7.7± 1.4

7.7 ± 1.4

136.8 ± 14.2

136.7± 14.3

76.3 ± 9.6

76.4 ± 9.6

4449 (68.2)

4420 (67.9)

253 (3.9)

269 (4.1)

1432 (22.0)

1462 (22.5)

385 (5.9)

356 (5.4)

Gerasimos (2022) [15]

RCT

7352

3686

3666

64.4±  9.34

65.1± 9.41

2528 (68.5)

2577 (70.2)

32.28± 6.2

31.84± 5.9

7.8± 1.4

7.79± 1.3

135.7± 13.7

135.3± 13.9

77.12± 9.6

76.41± 9.9

2672 (72.4)

2605 (71)

113 (3)

145 (3.9)

715 (19.3)

739 (20.1)

N/A

N/A